Dose escalation and DMC [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2020-01-07 11:18  – Posting: # 21064
Views: 944

Hi Pharma_88,

I agree with what Ohlbe wrote.

Note that the decision on whether or not to proceed to the next cohort must not be done at the clincal site but by an external Data Monitoring Committee (DMC). See also the EMA’s Guideline.

Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
20,635 posts in 4,324 threads, 1,434 registered users;
online 22 (0 registered, 22 guests [including 13 identified bots]).
Forum time: 10:14 UTC (Europe/Vienna)

Facts do not cease to exist because they are ignored.    Aldous Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5